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Abstract
Background
Congenital cytomegalovirus (cCMV) infection is the most prevalent congenital infection
acquired worldwide, with higher incidence in developing countries and among HIV-exposed
children. Less is known regarding vertical transmission of parvovirus B19 (B19V) and
enterovirus (EV). We aimed to assess the prevalence of CMV, B19V and EV vertical trans-
mission and compare results of screening of congenital CMV obtained from two different
specimens in a semirural Mozambican maternity.
Methods
A cross sectional study was conducted among pregnant mothers attending Manhic¸a District
Hospital upon delivery. Information on maternal risk factors was ascertained. Dried umbilical
cord (DUC) samples were collected in filter paper for CMV, B19V and EV detection by real-
time polymerase chain reaction (RT-PCR), and nasopharyngeal aspirates (NPA) to test
for CMV by RT-PCR. Maternal blood samples and placental biopsy samples were also
obtained to investigate CMV maternal serology, HIV status and immunopathology.
Results
From September 2014 to January 2015, 118 mothers/newborn pairs were recruited. Preva-
lence of maternal HIV infection was 31.4% (37/118). CMV RT-PCR was positive in 3/115
PLOS ONE | https://doi.org/10.1371/journal.pone.0194186 March 14, 2018 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Madrid L, Varo R, Maculuve S,
Nhampossa T, Muñoz-Almagro C, Caldero´n EJ, et
al. (2018) Congenital cytomegalovirus, parvovirus
and enterovirus infection in Mozambican newborns
at birth: A cross-sectional survey. PLoS ONE 13(3):
e0194186. https://doi.org/10.1371/journal.
pone.0194186
Editor: Soren Gantt, University of British Columbia,
CANADA
Received: December 10, 2017
Accepted: February 26, 2018
Published: March 14, 2018
Copyright: © 2018 Madrid et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Data are originally
from the PIPAC study and are restricted since it
contains sensitive patient information. To request
access to the data, please contact the Internal
Scientific Committee and Local Ethical Committee
of Centro de Investigac¸ão de Manhic¸a (+258
823041570) and from National Ethical Committee
of Mozambique (+258 214308114/21427131). The
authorisation of these two ethics committees is
required for data access. The authors of the PIPAC
(2.6%) of DUC samples and in 3/96 (6.3%) of NPA samples obtained from neonates. The
concordance of the RT-PCR assay through DUC with their correspondent NPA sample was
moderate (Kappa = 0.42 and p<0.001. No differences on cCMV prevalence were found
among HIV-exposed and unexposed. All (100%) mothers were seropositive for CMV IgG.
RT-PCR of EV and B19V in DUC were both negative in all screened cases. No histological
specific findings were found in placental tissues. No risk factors associated to vertical trans-
mission of these viral infections were found.
Conclusions
This study indicates the significant occurrence of vertical transmission of CMV in southern
Mozambique. Larger studies are needed to evaluate the true burden, clinical relevance and
consequences of congenital infections with such pathogens in resource-constrained
settings.
Background
Despite the impressive reduction in child mortality in the last decades, neonatal mortality has
declined more slowly and now accounts for nearly half (45%) of all under-5 child deaths[1].
Congenital and perinatal infections are well-known causes of neonatal morbidity and mortal-
ity and stillbirths in high-income countries (HIC)[2–4]. However, estimates of the global bur-
den of congenital infections and attributable stillbirths, neonatal disease, disability or deaths
due to mother-to-child transmission (MTCT) of these infections in low-income countries
(LIC) are limited on account of a generalized scarcity of data[5]. Despite the positive impact in
terms of health outcomes shown by the introduction of screening and treatment policies for
several pregnancy-relevant infections such as human immunodeficiency virus (HIV), syphilis
or malaria[6, 7]; pathogens that may also be vertically transmitted beyond these infections are
rarely the focus of clinical practice and research[8, 9].
Several viruses, including among others cytomegalovirus (CMV), parvovirus B19V (B19V)
and enterovirus (EV), may cause mild and self-limiting clinical manifestations among infected
pregnant women, but more severe or even life-threatening disease in their offsprings. The Zika
virus epidemic of 2016 in Latin America has contributed to highlight the emerging threat that
maternal viral infections may carry for the health of the foetus and newborn[10].
Despite being the most prevalent congenital infection worldwide, congenital CMV infec-
tion (cCMV) remains largely neglected in the developed and developing world[11]. Although
the global prevalence of cCMV has been reported to vary from approximately 0.2% to 2%
(mean 0.65%), most of these studies have been conducted in high-income regions of Europe,
USA or Japan were prevalence of cCMV ranges between 0.6–0.7%[12–14]. Data from LIC var-
ies substantially, with some estimates peaking at 6–14%[15–17]. Higher overall rates of cCMV
are found in countries with higher maternal CMV seroprevalence[12, 13, 18] and among
infants exposed to HIV during pregnancy. Indeed, maternal HIV infection is thought to signif-
icantly increase (from 2.3% to 10.3%) the prevalence of cCMV in those HIV-exposed infants
compared to those born to HIV-negative mothers, both in industrialized countries and also in
LIC[19–23]. Furthermore, CMV infection seems to play a role as a cofactor for HIV disease
progression in HIV/CMV co-infected newborns[24].
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Different methods have been evaluated for cCMV screening based on saliva, urine and
blood specimens, being saliva and urine the generally considered most appropriate samples
[25]. Virus isolation from saliva or urine in rapid culture has been traditionally considered the
standard method for identification of infants with cCMV but such methods appear unfeasible
to perform for large screening efforts [26]. In contrast, real-time polymerase chain reaction
(RT-PCR), also considered as gold standard [26–28], allows large numbers of specimens to be
screened at a relatively low cost. However, RT-PCR based methods applied to dried-blood-
spot (DBS), tested in countries where DBS are routinely collected for newborn metabolic
screening, have shown a low sensitivity as a screening methodology[26]. Dried umbilical cord
(DUC) sample-based PCR assays have demonstrated utility for diagnosis of cCMV, as part of
retrospective investigations of the underlying aetiology of hearing impairment[29, 30]. Other
samples such as nasopharyngeal aspirates (NPA) which are easily obtained and simple to store
have been used to investigate respiratory pathogens of public health importance[31, 32].
However, to our knowledge, NPAs have not been evaluated as a screening methodology for
cCMV diagnosis, although the Child Health and Mortality Prevention Surveillance Network
(CHAMPS) aiming to know cause of death through innovative techniques such as the mini-
mally invasive tissue sampling (MITS), proposes NPA as a standard specimen for diagnosis of
cCMV[33, 34].
Knowledge gaps regarding the burden of other congenital infections associated to fatal foe-
tal outcomes, such as B19V and EV, remain significant. B19V can cause a variety of foetal com-
plications including spontaneous abortion, non-immune hydrops foetalis or intrauterine foetal
death[35]. The epidemiology of B19V infection in pregnancy has been well studied in industri-
alized countries whereby prevalence has been estimated to vary from 1 to 5% in pregnant
women with transmission rates to the foetus ranging between 17–33%[36]. However, the bur-
den of this infection during pregnancy in LIC has been rarely documented and studies investi-
gating in these settings active B19V infection in newborns have not been conducted.
Enteroviruses, which include coxsackieviruses and echoviruses, cause about one billion
infections every year worldwide but their consequences during pregnancy have been seldom
described[37]. Transplacental transmission of EV has been associated to stillbirths, non-
immune hydrops foetalis and also severe neonatal infections, although the epidemiology and
characterization of neonatal outcomes is not well documented[37].
Although data in LIC remain insufficient, higher burden of congenital infections may be
assumed in regions like Southern Mozambique where HIV is highly prevalent and effective
vaccines against pathogens such as rubella are partially or even not implemented[15, 38–41].
This is a pilot study exploring congenital acquisition of CMV, B19V and EV determined at
birth. We additionally aimed to compare the results of two simple screening methodologies
using RT-PCR for cCMV investigation, using DUC and NPA specimens obtained from the
newborns.
Methods
Study site
The study was conducted in Manhic¸a, a semi-rural site in Southern Mozambique. The Man-
hic¸a Health Research Centre (CISM) runs a Demographic Surveillance System (DSS) in the
area linked to a Hospital Morbidity Surveillance System (HMSS) ongoing at the Manhic¸a Dis-
trict Hospital (MDH) including all admitted children. A detailed description of MDH, CISM
and the study area can be found elsewhere[42]. MDH is the referral hospital for the Manhic¸a
district, covering a population of circa 183,000 inhabitants. The MDH includes adult and pae-
diatric wards, together with a maternity, where an average of 3500–4000 deliveries takes place
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annually. Around 85% of all deliveries are institutionalized (A. Nhacolo, personal communica-
tion). It also includes an outpatient department and an antenatal care (ANC) clinic where
pregnant women are routinely followed. As part of the National policy, all pregnant women
are invited to attend ANC clinic during their pregnancy, where HIV testing and syphilis
screening are routinely offered. Malaria transmission of moderate intensity is perennial with
some seasonality and, intermittent preventive treatment during pregnancy (IPTp) for malaria
prevention is recommended[42]. HIV prevalence in Manhic¸a district is amongst the highest in
the world, with rates estimated at around 29% at the ANC clinic [40]. In 2013, MDH intro-
duced WHO-recommended Option B+ for the prevention of mother-to-child HIV transmis-
sion[43], which is offered to mothers free of charge. No proactive strategies to screen for risk
factors of neonatal sepsis or to prevent it are currently implemented in Mozambique.
Study design and population
This observational pilot study was conducted at the delivery wards of MDH, between Septem-
ber 15th 2014 and January 15th 2015, running continuously during working hours (8:00–16:00)
and working days. We recruited pregnant women upon delivery (regardless of gestational age
(GA) and their offspring. Participants were eligible for inclusion if they were>18 years old
and able and willing to participate in the study and to provide informed consent after an expla-
nation of the study. As this was a pilot study, in order to obtain a more representative sample
of the study population, only the first three women seen every day were approached for
recruitment.
Definitions
Gestational age was defined using fundal height, measured from the top of the mother’s uterus
to the top of the mother’s pubic symphysis and assessed by a nurse specialist in maternal child
health. A preterm baby was defined as that with a gestational age at birth of<37 weeks and a
stillbirth case as an intrauterine death occurring after 28 weeks of GA. Low-birth weight was
defined as weight at birth<2.500 grams[44]. Microcephaly was defined following the WHO
growth standards[45]. Congenital CMV, B19V or EV infections were defined as detection of
viral DNA/RNA by RT-PCR in dried cord umbilical samples obtained from neonates at birth
[33]. Although cCMV diagnosis through NPA has not been validated, we also explored preva-
lence of CMV through positive RT-PCR in NPA specimens. Positive HIV status was defined
according to national guidelines, which required for mothers two positive rapid testing (an ini-
tial discriminatory diagnostic test (Determine1) and a confirmatory test(Unigold1); and for
children 18 months of age a positive rapid test in addition to a confirmatory positive PCR
test.
Study procedures
A placental biopsy and two drops of umbilical cord blood collected in filter paper (Whatman
9031, Florham Park, NJ) were obtained immediately after delivery in order to determine
DNA/RNA of CMV, B19V and EV and assess placental histopathology. In addition, a NPA
was collected from neonates within the first two hours from birth, using a bulb aspiration kit
conveniently pre-filled with sterile saline (M-PRO NPAK nasopharyngeal aspiration kit1). At
least 1ml of NPA specimen mixed with sterile saline was collected and stored with the objective
of screening for CMV DNA. A blood sample was collected from mothers for assessing anti-
CMV antibodies. Maternal HIV status was determined and recorded if not previously regis-
tered in antenatal source documents. Other screening test results routinely performed at the
Congenital cytomegalovirus, parvovirus and enterovirus infection in Mozambican newborns at birth
PLOS ONE | https://doi.org/10.1371/journal.pone.0194186 March 14, 2018 4 / 17
ANC clinic, such as syphilis screening (using Rapid Plasma Reagin) or haemoglobin determi-
nation were also recorded.
DNA extraction and real time -PCR for viral amplification. CMV and B19V DNA and
EV RNA were extracted from 1 drop of DUC (around 50 ul) and CMV from 400 ul of NPA
specimen by using the NucliSENS1 easyMag1 (bioMe´rieux, Marcy l’Etoile, France) instru-
ment according to the manufacturer’s procedure and eluted in 25 μl of elution buffer for DUC
and 50 ul for NPA. Samples were tested for the presence of CMV DNA, B19V DNA and EV
RNA with three different real-time PCR, CMV Q- PCR alert Kit1, Elitech Group Molecular
Diagnostics, RealStar1 Parvovirus B19V kit1, Altona Diagnostics and and a published in-
house real-time RT-PCR assay for EV detection [46]. Positive results with cycle threshold
values above 40 were classified as negative. Appropriate positive and negative controls were
included in all the experiments. Samples were considered as valid when a clear positive or neg-
ative result was obtained.
Seroprevalence of CMV among pregnant women. Serum collected from the mothers
was tested for the presence of anti-CMV immunoglobuline G (IgG) antibodies (AB) using the
electrochemiluminescence immunoassay “ECLIA” intended for use on Elecsys and cobas
immunoassay analyzers, according to the manufacturer’s instructions. Positive, negative, and
cut-off controls were included in all runs, and positive samples were retested to confirm initial
positive result.
Placental biopsy. A placental biopsy was obtained with a scalpel blade and immediately
placed into 10% buffered formalin for transport to the laboratory. Each placental sample was
embedded in paraffin wax, sectioned in 5μm tissue pieces and stained with standard haema-
toxylin–eosin for histopathologic examination. Different histopathological parameters were
assessed including a macroscopic description (weight, oedema, haemorrhage, infarct and calci-
fications) and a microscopic description (inflammation and presence of microorganisms).
Additional sections were saved for histochemical staining (PAS, Grocott and Gram) per-
formed in an automated stainer (BenchMark Special Stains- Ventana Roche), following com-
mercial recommendations. An immunohistochemical assay was performed on formaline-
fixed paraffin-embedded tissue sections according to standard procedures, using the Ventana-
Roche automated immunostainer system (BenchMark XT-Ventana Roche1). Antigen
retrieval was performed by heat-induced epitope retrieval and B19V (Master Diagnostica1,
Granada, SP) and CMV (Cell Marque1, Rocklin, CA, USA) antibodies were applied according
to manufacturing instructions.
Infant follow-up. Clinical examination of all newborns, including the evaluation of head
circumference and Apgar score at minute 1, 5 and 10, was performed at birth. Dubowitz score
for postnatal GA determination was done in live neonates at least 12h after birth[47]. Maternal
and child HIV status were registered. All participants were followed using the HMSS in order
to check any hospital admissions to MDH during the first six months after birth. No specific
imaging or hearing screening was performed in these children.
Statistical analysis
All data were prospectively collected using standardized questionnaires, which were double
entered in specific study databases, created using Openclinica software. Discrepancies were
solved after comparison with the original source documents by a senior data clerk, and in
close collaboration with the study clinicians. Statistical analyses were performed using Stata
14.1 (Stata Corp., College Station, TX). Study variables were counted and summarized in fre-
quency tables. Univariate and multivariate analyses were performed to identify risk factors for
CMV, B19V and EV neonatal infection, separately. Firth logistic regression was used in order
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to address issues of separability, small sample sizes and bias of the parameter estimates. Vari-
ables that were found to be significantly associated with CMV, B19V and EV acquisition in the
univariate analysis together with those related at a significance level of p<0.10 were entered
into a multivariate model. Agreement between the results of DUC RT-PCR assays and those of
NPA RT-PCR was assessed through Kappa statistic.
Ethical considerations
This protocol and all supporting documentation (Informed consent documents, Study ques-
tionnaires) were approved by the local bioethics committee of CISM (Comite´ Institucional de
Bioe´tica para Sau´de) and by the National Bioethics Committee of Maputo in Mozambique,
and by the Ethics Committee of the Hospital Clı´nic in Barcelona, Spain. Participants were
asked to express their willingness to participate in the study by signing (or thumb-printing in
case they were illiterate) a consent form. Participation in this study was voluntary, and study-
related procedures did not interfere with the pregnant women’s or children’s standard clinical
care.
Results
Maternal characteristics
During the study period, 118 pregnant women were recruited upon delivery at MDH (Fig 1).
Table 1 summarizes the socio-demographic and clinical characteristics of participant mothers.
Median age of recruited women was 22 years (Interquartile range, IQR 19–29), with >75%
being younger than 30 years of age. Nearly a third of women (31.4%, 37/118) were confirmed
HIV positive and only one of 118 had a positive syphilis test. Malaria test results were regis-
tered as negative in 5/118 women and no information about this disease was available for the
rest of mothers. CMV IgG AB were detected in all (100%) women.
Distal villous hypoplasia was observed in 27/117 (23.0%) of placental tissue samples evalu-
ated. Neither microorganisms nor other significant findings were detected after evaluating tis-
sue sections with standard tissue staining or in the immunohistochemical studies (Fig 2). No
maternal risk factors associated to neonatal cCMV were found in the univariate analysis and
thus, multivariate analysis was not performed (Table 1).
Neonatal outcomes and infant follow-up
One hundred and eighteen delivery outcomes from the 118 pregnant women were recorded
(100%) at MDH. Characteristics of neonates born of mothers participating in the study are
shown in Table 2. Neonatal outcomes included 110 live term babies, 7 preterm and 1 case of
stillbirth born at 41 weeks of GA, whose mother refused permission to sample the foetus.
Twenty-one (17.8%) newborns had low-birth-weight and three of them (2.5%) presented
microcephaly at birth[48].
At least one specimen was collected from 117 neonates. A hundred and fifteen of the 117
DUC samples obtained were valid for viral determination. All of them were negative for B19V
and EV.
Three of the 115 (2.6%) valid DUC samples were positive for CMV. This virus was also
detected in 6/96 (6.3%) valid NPA samples obtained. A total of 7/117 (6.0%) newborns tested
had at least one positive sample for CMV. Prevalence of cCMV infection measured by DUC
among HIV-exposed neonates was 2.7% (1/37) and 8.1% (3/37) when CMV was detected
through NPA, although no significant difference was found compared to the prevalence
among HIV-unexposed in both cases (Table 1). One of the NPA-CMV positive cases was born
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preterm and with low birth weight while all neonates DUC-CMV positive were healthy at
birth. CMV infection was associated to a higher risk of microcephaly at birth when CMV
was determined by NPA (OR 9.65, 95% CI 1.07–87.12, p = 0.04) in the univariate analysis
(Table 2).
Through HMSS, 7/117 infants born to mothers participating in the study were detected as
admissions at MDH at least once during their first 6 months of life (Table 2). Two of them
admitted within the first 24h after birth died due to clinical sepsis. Other causes of admission
included perinatal asphyxia, bronchiolitis, diarrhoea and malaria. Among neonates were CMV
was detected, only the preterm baby with a positive NPA for CMV was admitted at birth. In all
of these cases, children were discharged fully recovered. No additional follow-up investigations
were conducted.
Comparison of dried umbilical cord and nasopharyngeal aspirate RT-PCR Assays for
CMV determination. A total of 94 pairs of samples (DUC and NPA) from 94 neonates were
Fig 1. Study profile. ANC: antenatal clinics; IC: informed consent; One stillbirth whose mother refused to take samples. RT-PCR: real-time polymerase chain
reaction, DUC: dried umbilical cord, NPA: nasopharyngeal aspirate.
https://doi.org/10.1371/journal.pone.0194186.g001
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available for testing CMV by RT-PCR assay and comparing results. Of these, 2/94 neonates
(2.1%) were positive for CMV by any test. A newborn with a positive RT-PCR assay through
DUC had a negative NPA result, and the NPA RT-PCR assay also identified four additional
neonates as infected although their DUC RT-PCR were negative (Fig 1). The overall concor-
dance of the RT-PCR assay through DUC with their correspondent through NPA was moder-
ate (Kappa = 0.42 and p<0.001).
Table 1. Socio-demographic and clinical characteristics of mothers participating in the study and univariate analysis of maternal risk factors associated to congeni-
tal CMV infection measured by different specimens.
Total mothers
recruited, n = 118
Mothers of neonates CMV
positive by DUC,n = 3ᶤ
Crude OR
(95%CI)ᵟ
p-
valueᵟ
Mothers of neonates CMV
positive by NPA,n = 6ᶽ
Crude OR
(95%CI)ᵟ
p-
valueᵟ
Socio-demographic
characteristics
n (%) n (%) n (%)
Age in years 0.61 0.61
< 21 51 (43.2) 2 (66.7) 1.00 4 (66.7) 1.00
22 to 29 40 (33.9) 0 (0) 0.23 (0.01–
4.92)
1 (16.7) 0.23 (0.01–
4.92)
30 27 (22.9) 1 (33.3) 1.05 (0.13–
8.42)
1 (16.7) 1.05 (0.13–
8.42)
Seconday or tertiary
education
30 (25.4) 0 (0.0) 0.40 (0.02–
8.06)
0.55 3 (50.0) 3.23 (0.68–
15.36)
0.14
Employment 6 (5.1) 0 (0.0) 2.34 (0.1150.28 0.59 0 (0.0) 1.92 (0.89–
41.36)
0.68
Obstetric History n (%) n (%) n (%)
Age of first pregnancy
(median±IQR))
18.0 (17–20) 18.0 (17–18) 0.91 (0.27–
3.11)
0.89 18.0 (18–18) 1.03 (0.76–
1.41)
0.84
Gravidity (mean±SD) 2.7 (±0.2) 3.7 (±2.2) 1.27 (0.81–
2.01)
0.30 1.5 (±0.2) 0.63 (0.31–
1.29)
0.21
Previous abortion n(%) 11 (9.3) 0 (0.0) 1.26 (0.61–
25.97)
0.88 0 (0.0) 0.75 (0.89–
14.43)
0.85
History of current pregnancy n (%) n (%) n (%)
At least 3 antenatal visits
during the pregnancy
69 (58.5) 2 (66.7) 0.78 (0.98–
6.15)
0.81 5 (83.3) 1.22 (0.19–
8.01)
0.83
Gestational hypertension 7 (6.1) 0 (0.0) 2.73 (0.12–
62.25)
0.53 1 (16.7) 3.38 (0.47–
24.33)
0.23
Vaginal discharge 2 (1.7) 0 (0.0) 6.31 (0.25–
157.63)
0.26 0 (0.0) 2.72 (0.12–
62.86)
0.53
Investigations n (%) n (%) n (%)
Syphilis positive 1 (0.5) 0 (0.0) 9.95 (0.34–
290.3)
0.32 0 (0.0) 5.12 (0.19–
140.92)
0.33
HIV positive 37 (31.4) 1 (2.7) 1.26 (0.16–
9.89)
0.83 3 (50.0) 2.19 (0.46–
10.30)
0.32
HIV positive in HAART 33 (89.2) 1 (100.0) 1.25 (0.11–
4.43)
0.86 3 (100.0) 2.60 (0.48–
14.04)
0.25
Anemia (<11g/dL) 55 (72.4) 0 (0.0) 0.13 (0.01–
3.26)
0.21 2 (66.7) 0.59 (0.07–
4.88)
0.63
CMV IgG serum antibodies 118 (100) 3 (100) 0.03 (0.00–
1.81)
0.09 6 (100) 0.07 (0.06–
3.92)
0.20
IQR (interquartile range). SD: standard deviation. HAART: highly active antiretroviral therapy. CMV: cytomegalovirus. DUC: Dried umbilical cord.
ᶤResults based on 115 valid DUC samples. NPA: Nasopharingeal aspirate.
ᶽResults based on 96 valid NPA samples OR: odds ratio. CI; confindence intervals.
ᵟOR and P-value derived from Firth logistic regression.
https://doi.org/10.1371/journal.pone.0194186.t001
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Discussion
This study is a first attempt at proactively investigating vertical transmission of CMV, B19V
and EV in Mozambique. The study was an opportunistic attempt to explore congenital trans-
mission of these viruses, and was not specifically designed to evaluate the performance of the
RT-PCR method of identification of cCMV in neonates as compared with the “gold-standard”
for the detection of CMV (isolation of the virus in rapid cultures or PCR assay) since that has
already been demonstrated[49–51]. The study shows a prevalence of cCMV infection assessed
through dried umbilical cord samples of 2.6% and through NPA of 6.3%. Although specimens
utilized in this study have not been validated for their use in cCMV diagnosis, they highlight a
high burden of vertical CMV transmission. Contrarily, B19V and EV congenital transmission
in the newborns was not found in this cohort although only DUC samples were analyzed. The
prevalence of cCMV in this study detected through DUC was likely underestimated, as it has
been demonstrated that real-time dried-blood-spot PCR assay has a lower sensitivity com-
pared with the standard saliva rapid culture[26]. The dried umbilical cord samples have previ-
ously been used for retrospective studies to diagnose cCMV[29, 30] and although this sample
type has never been compared to other accepted specimens for cCMV diagnosis, it would how-
ever be reasonable to assume that a positive DUC sample is likely a true positive. On the other
hand, NPA has never been previously assessed as a specimen valid for cCMV diagnosis. A sig-
nificant limitation of this study includes the fact that up to 30% of CMV-seropositive women
will secrete CMV in their vaginal fluid, something that could possibly contaminate with CMV
Fig 2. Placental histology from an infant with cytomegalovirus detected in dried umbilical cord blood. Distal villous
hypoplasia: many terminal villi are extremely small, with reduced stroma and capillaries number. No inmunohistochemical
evidence of CMV could be found.
https://doi.org/10.1371/journal.pone.0194186.g002
Congenital cytomegalovirus, parvovirus and enterovirus infection in Mozambican newborns at birth
PLOS ONE | https://doi.org/10.1371/journal.pone.0194186 March 14, 2018 9 / 17
the nasopharynx of neonates[52]. Thus, the prevalence of 6.3% found in this study through
NPA may potentially overestimate the true prevalence.
If the cCMV prevalence found through DUC can be a proxy of the true prevalence, these
findings suggest higher prevalence rates than those reported in newborns from industrialized
countries (<1%)[14] and falls within the range reported in a systematic review for developing
countries (0.6%–6.1%)[53]. However, that review excluded studies reporting data from high
at-risk populations for CMV transmission, such as HIV infected mothers, and restricted inclu-
sion to studies having used the recommended gold standard specimens (saliva and urine) and
techniques (cultures and PCR)[54]. Although it is likely that our cCMV prevalence was under-
estimated for the aforementioned reasons, other studies conducted in HIV endemic areas
have reported similar congenital CMV prevalence to those shown here. A study conducted in
Table 2. Clinical characteristics of neonates born to mothers participating in the study.
Neonates at birth
n = 118
Neonates CMV positive by
DUC n = 3ᶧ
Crude OR
(95%CI)ᵟ
p-
valueᵟ
Neonates CMV positive by
NPA n = 6ᶽ
Crude OR
(95%CI)ᵟ
p-
valueᵟ
Clinical characteristics of
newbornsᶤ
n (%) n (%) n (%)
Gestational age at birth (live
birth)
0.65 0.21
Term newborn 110 (94.1) 3 (100.0) 1.00 5 (83.3) 1.00
Pre term newborn 7 (5.9) 0 (0) 2.01 (0.95–
42.62)
1 (16.7) 3.54 (0.49–
25.53)
Stillbirth 1 (0.9) 0 (0) _ _ 0 (0) _ _
Low birth weight (<2500gr) 21 (17.8) 0 (0) 0.61 (0.03–
12.21)
0.75 1 (16.7) 1.23 (0.19–
8.09)
0.22
Head circumference in cm
(mean±SD)
35.6 (0.4) 39.7 (5.2) 1.13 (0.99–
1.29)
0.08 36.2 (2.9) 2.69 (0.12–
62.15)
0.54
Microcephaly 3 (2.5) (0) 4.43 (0.19–
103.20)
0.35 1 (16.7) 9.65 (1.07–
87.12)
0.04
Perinatal asphyxia 2 (1.7) 0 (0) 10.62 (0.36–
309.66)
0.17 0 (0) 2.69 (0.12–
62.15)
0.54
Jaundice 0 (0) 0 (0) _ _ 0 (0) _ _
Purpura 0 (0) 0 (0) _ _ 0 (0) _ _
Dubowitz neurological score
(mean±SD)ˠ
30.8 (0.2) 31.0 (0.8) 0.88 (0.64–
1.22)
0.46 31.7 (1.02) 1.14 (0.79–
1.65)
0.47
Malformations at birth 2 (1.7) 0 (0) 6.25 (0.25–
156.21)
0.26 0 (0) 2.69 (0.12–
62.15)
0.54
Sick at birth 2 (1.7) 0 (0) 6.25 (0.25–
156.21)
0.26 0 (0) 2.69 (0.12–
62.15)
0.54
Outcome
Admitted first 6 months of life 7 (5.9) 0 (0) 2.01 (0.95–
42.62)
0.65 1 (16.7) 3.55 (0.49–
25.52)
0.21
Death after birthᶬ 2 (1.7) 0 (0) 6.25 (0.25–
156.21)
0.26 0 (0) 2.69 (0.12–
62.15)
0.54
CMV: cytomegalovirus. DUC: Dried umbilical cord.
ᶧResults based on 115 valid DUC samples. OR: odds ratio. CI; confidence intervals.
ᵟOR and P-value derived from Firth logistic. NPA: Nasopharingeal aspirate.
ᶽResults based on 96 valid NPA samples.
ᶤResults based on 117 patients. Mother of a stillbirth refused to take sample of the baby.
ˠSuboptimal neurological score following Dubowitz: <30.5.
ᶬ Death (including stillbirth and any deaths in the first 6 months after birth)
https://doi.org/10.1371/journal.pone.0194186.t002
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Nigeria found a rate of 3.8% among neonates born to mothers with a low prevalence of HIV
(4.8%)[55]. High prevalence of cCMV in HIV-exposed infants has been previously reported in
two settings (South Africa and Zambia) with a maternal HIV prevalence similar to the one
documented in our study area[23, 56–58]. The South African study was conducted among 748
HIV-exposed infants found a cCMV prevalence of 2.9%. No comparison with HIV-unexposed
was performed [23]. Overall prevalence of cCMV among high-risk newborns admitted to a
referral neonatal unit in Zambia was 3.8%, and 11.4% in those infants exposed to maternal
HIV (Adjusted OR 6.66, 95% CI 2.13–20.9)[58]. HIV prevalence in our maternal cohort was
very high (31.4%) and almost 90% of mothers were under highly active antiretroviral therapy
(HAART), possibly explaining why the prevalence of cCMV was not higher among HIV-
exposed newborns and why differences between HIV-exposed and unexposed neonates
(2.7% vs. 2.6%%, OR 1.26 95% CI 0.16–9.89, p = 0.83) were not found[59]. Reasons to explain
the difference between Zambian study results and our findings could be that the Zambian
study was performed on admitted and therefore sick neonates and our study was conducted at
time of birth. Another reason may be a better immune status of our HIV-infected mothers
although information about HAART in this Zambian study was not available[58]. Immuno-
suppression in HIV-infected pregnant women likely leads to increased incidence of reinfection
or reactivation, or prolonged CMV viral shedding, lengthening the opportunity for congenital
transmission[21, 60]. Moreover, an association of CMV transmission with advanced maternal
immunosuppression has been previously described[23].
No risk factors independently associated with cCMV were found. Primiparity, acute pla-
cental malaria, HIV-exposure and jaundice have all been reported as independent risk factors
for cCMV infection by other authors[19, 28, 58, 61]. Caution is needed when interpreting our
findings, since sample size was small and likely insufficient to detect significant differences
among infected and uninfected neonates. It has been estimated that 90% of infected newborns
do not have obvious clinical signs of CMV congenital infection and of them, only 15% will
develop long-term neurological sequelae, especially, neurosensory hearing loss[14]. However,
no further examinations and follow-up were performed beyond birth and burden of hearing
loss was not explored. cCMV infection is an important cause of hearing loss and better strate-
gies to detect children at risk of this complication in LIC should be developed.
Maternal CMV IgG seroprevalence in this study was 100%. Immune status of mothers in
our cohort prior to pregnancy was unknown. In these cases, isolated detection of CMV IgG or
detection of specific IgM AB are inadequate single measures to diagnose maternal primary
infection[28]. Estimates suggest that around 75% of all cCMV cases in industrialized countries
occur in babies born to women with non-primary maternal infection (those women who are
CMV seropositive before pregnancy[28, 62–64]) and the risk of intrauterine transmission has
been estimated at 1% in CMV-seropositive mothers[14]. IgG CMV seroprevalence in develop-
ing countries is generally over 90% by adolescence and over 95% by early adulthood[53] and it
has been demonstrated that the incidence of cCMV infection is parallel to maternal seropreva-
lence[28], suggesting that most of cases of vertical transmission of this virus result from non-
primary maternal infection and may be due to reactivation of latent virus or reinfection with a
new cytomegalovirus strain[28, 62–64]. This is the reason behind the current recommenda-
tions issued by The International Congenital Cytomegalovirus Recommendations Group of
not conducting universal serological screening of pregnant women for primary CMV infec-
tion[28].
Maternal infections with B19V, CMV and EV have been associated with intrauterine foetal
death[65]. This study did not focus in cases of abortion and only one stillbirth was registered
during recruitment, which hinders our capacity to associate them to the aforementioned
pathogens.
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Our findings suggest a low prevalence of B19V and EV infections in Southern Mozam-
bique. No B19V congenital infection in newborns was found in this study. To our knowl-
edge, no prospective screening of congenital B19V and EV infections among neonates in
developing countries has been conducted to date. A South African study exploring preva-
lence of B19V infection among pregnant women found 20 asymptomatic neonates born to
IgM positive mothers, although no samples from newborns were obtained[66]. Different
African studies on maternal B19 V seroprevalence found IgG AB between 24.9 and 80% and
IgM between 3 and 19%[66–70]. Unfortunately, maternal seroprevalence was not performed
in this study and further research should be done in order to know the real burden of con-
genital B19V.
Similarly, all babies were negative for EV and maternal seroprevalence studies were not per-
formed. Data on incidence and consequences of EV during pregnancy and clinical outcomes
are globally scarce. Case reports and small case series have suggested that EV infection may
cause foetal loss, and maternal infections during the 2nd and 3rd trimester may also lead to
in utero foetal anomalies and death, but also to severe neonatal infections[37]. However, no
prospective studies investigating EV maternal prevalence and risk of transmission have been
conducted.
The few and unspecific anatomopathological findings documented in this study, consisting
on an accelerated placental maturation, could have resulted from a variety of causes, including
maternal preeclampsia or other states of maternal vascular underperfusion, or, more likely in
our setting, due to malnutrition or infectious such as HIV or malaria. However, the lack of
ovular membranes and umbilical cord in placental samples did not allow ruling out possible
infections of these tissues.
Our study has several limitations. First, diagnosis of cCMV through DUC specimen is a
methodology not recommended for neonatal CMV screening, particularly as urine and saliva
have been demonstrated to be the most reliable specimens [26, 28]. The use of NPA for cCMV
has not been validated and this specimen could be contaminated by maternal secretions con-
tained CMV, leading to an overestimation of the true cCMV prevalence. However, a similar
issue occurs with saliva samples, since the risk of contamination of saliva samples with breast
milk exists. We however chose to use RT-PCR methods, with known good performance, in
those samples available from the study, both because the kind of samples and the molecular
screening techniques could be a good approach to study several viruses simultaneously. Fur-
ther studies to validate these particular specimens for cCMV diagnosis would help to know
their specificity and positive predictive value, and shed a light on why an important number of
samples provided invalid results. Second, further follow-up and additional investigations
beyond six months of life were not performed and hearing impairment, which is frequently
progressive and usually develops later during infancy, was not measured, leading to a potential
underestimation of CMV- associated morbidity. Third, the study lacked sufficient statistical
power to detect independent risk factors associated to higher risk of congenital CMV, B19V
and EV infections given the small sample size, and the few positive results. Additionally, it is
known that both, B19V and EV show seasonal or even epidemic patterns [71, 72]. Considering
that the epidemiology of these viruses in unknown in Mozambique, we may have failed, during
the short study period, to capture natural transmission of the pathogens. Finally, B19V and EV
were only assessed in dried umbilical cord samples at birth and maternal seroprevalence of
these viruses or their presence in other fluids such as amniotic fluid was not investigated.
Understanding also that these viruses may not be detected in cord blood in the absence of a
true viraemia, it appears difficult to properly correlate the burden of maternal infection and
the associated vertical transmission of these viruses. Thus, the prevalence observed in this
study could be importantly underestimated.
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In conclusion, despite the small sample size and the use of non-standard specimens, this
study demonstrates that the prevalence of vertical transmission of CMV may be high in south-
ern Mozambique, although further research is needed to assess its clinical relevance in this
area. Studies validating the sensitivity and specificity of NPA for CMV screening would be
required before considering it for clinical use. Congenital B19V and EV infections seem to be
less prevalent in this area. Further research to evaluate the consequences of vertical transmis-
sion of these viral infections in resource-constrained settings is needed.
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